Jefferies analyst Matthew Taylor upgraded Abbott (ABT) to Buy from Hold with a price target of $145, up from $143. The firm says that while Abbott’s Q2 report and outlook were “underwhelming,” the corresponding share selloff is “too punitive.” Jefferies recommends taking advantage of the pullback as it believes the company’s growth can accelerate in 2026. The stock’s current valuation is “compelling for a quality franchise with multiple growth drivers,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories Reports Strong Q2 2025 Results
- Abbott’s Earnings Call: Strong Growth Amid Challenges
- Abbott Laboratories: Temporary Challenges Amid Strong Long-Term Growth Prospects Justify Buy Rating
- Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges
- Morning Movers: PepsiCo gains following second quarter results